The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity data, leading to an absence of evidence-based guidelines.
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
Annals of Oncology | | E.S.M. van Aken, B. Devnani, A. Prelaj, L. Castelo-Branco, C.A.M. Marijnen, D. Martins-Branco, M.A. Gambacorta, A. Lamarca, K. Harrington, G. Minniti, M. Hecht, D. Papamichael, M. Krause, R. Cathomas, K. Lindberg, S.M. O’Cathail, U. Nestle, J. Barriuso, S. Nowicki, C. Rödel, P. Boot, C. Belka, U. Ricardi, F. Lordick, D. De Ruysscher, G. Pentheroudakis, M.C. de Jong, A.K. Gandhi
Topics: immunotherapy, targeted-therapy, radiation